Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

[Developments in HPV vaccination].

de Melker H, Kenter G, van Rossum T, Conyn-van Spaendonck M.

Ned Tijdschr Geneeskd. 2012;156(47):A5410. Review. Dutch.

PMID:
23171565
3.

The economic impact of HPV vaccines: not just cervical cancer.

Myers ER.

Am J Obstet Gynecol. 2008 May;198(5):487-8. doi: 10.1016/j.ajog.2008.03.056. No abstract available.

PMID:
18455522
4.

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.

Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.

5.

[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].

Westra TA, Daemen T, Postma MJ, Wilschut JC.

Ned Tijdschr Geneeskd. 2009;153:A356. Review. Dutch.

PMID:
19930733
6.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

PMID:
17682997
7.

Cost-effectiveness of human papilloma virus vaccination in Iceland.

Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.

Acta Obstet Gynecol Scand. 2009;88(12):1411-6. doi: 10.3109/00016340903322750.

PMID:
19900074
8.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
9.

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.

Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.

Vaccine. 2011 Nov 8;29(48):8929-36. doi: 10.1016/j.vaccine.2011.09.055. Epub 2011 Sep 22.

PMID:
21945961
10.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

PMID:
19571256
11.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
13.

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Brisson M, Van de Velde N, De Wals P, Boily MC.

Vaccine. 2007 Jul 20;25(29):5399-408. Epub 2007 May 22.

PMID:
17561316
14.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
15.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
16.

Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?

de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M.

Eur J Cancer. 2011 Feb;47(3):428-35. doi: 10.1016/j.ejca.2010.09.030.

PMID:
20971633
17.

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.

Vaccine. 2012 Feb 27;30(10):1813-22. doi: 10.1016/j.vaccine.2012.01.001. Epub 2012 Jan 10.

PMID:
22240341
18.

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.

Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG.

Vaccine. 2007 Aug 14;25(33):6245-56. Epub 2007 Jun 21.

PMID:
17630049
19.

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.

Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.

Vaccine. 2009 Jul 30;27(35):4776-83. doi: 10.1016/j.vaccine.2009.05.085. Epub 2009 Jun 17.

PMID:
19539578
20.

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.

BJOG. 2012 Jan;119(2):177-86. doi: 10.1111/j.1471-0528.2011.03036.x. Epub 2011 Jul 28.

Supplemental Content

Support Center